A safety trial of high dose glyceryl triacetate for Canavan disease

Keyphrases

• High Dose 100%
• Acetate 100%
• N-acetylaspartate 100%
• Canavan Disease 100%
• Safety Trial 100%
• Glyceryl Triacetate 100%
• Aspartoacylase 66%
• No Toxicity 33%
• Neurodegenerative Diseases 33%
• Brain Injury 33%
• Enzyme Activity 33%
• Triglycerides 33%
• Disease Course 33%
• Late-onset 33%
• Clinical Status 33%
• Tremor 33%
• Autosomal Recessive 33%
• Degradative Enzymes 33%
• Early Infancy 33%
• Clinical Improvement 33%
• Safety Profile 33%
• Glycerol 33%
• Motor Improvement 33%
• Motor Function 33%
• Short Chain 33%
• Aspartic Acid 33%
• Long-term Efficacy 33%
• Acetate Acid 33%
• Intragastric Administration 33%
• Lipid Synthesis 33%
• Myelin Lipids 33%
• Acetate Precursor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Canavan Disease 100%
• Aspartoacylase 100%
• Triacetin 100%
• Diseases 100%
• Side Effect 50%
• Aspartic Acid 50%
• Triacylglycerol 50%
• Myelin 50%

Neuroscience

• Acetate 100%
• Triacetin 100%
• Canavan Disease 100%
• Aspartoacylase 40%
• Aspartic Acid 20%
• Tremor 20%
• Triacylglycerol 20%
• Neurodegenerative Disorder 20%
• Enzyme Activity 20%
• Myelin 20%
• Vertebral Column 20%